검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR)) Iovance Biotherapeutics, Inc.·Squamous Lntraepithelial Lesions o… ORR 5% |
|---|---|
Overview Program | E7 T Cell Receptor (TCR) |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Squamous Lntraepithelial Lesions of Vulv |
Overview Indication | Papillomavirus Infections; Oropharyngeal Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies.. Monoclonal antibodies (mAbs) targeting the Plasmodium falciparum circumsporozoite protein (CSP) are leading clinical candidates for malaria prevention in travelers, military personnel, and pregnant women. Off-target binding and pharmacokinetics (PK) are important considerations during… |
Toxicology CRS | Reported |
Clinical ORR | 5% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT02858310 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR)) Iovance Biotherapeutics, Inc.·Squamous Lntraepithelial Lesions o… ORR 5% |
|---|---|
Overview Program | E7 T Cell Receptor (TCR) |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Squamous Lntraepithelial Lesions of Vulv |
Overview Indication | Papillomavirus Infections; Oropharyngeal Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies.. Monoclonal antibodies (mAbs) targeting the Plasmodium falciparum circumsporozoite protein (CSP) are leading clinical candidates for malaria prevention in travelers, military personnel, and pregnant women. Off-target binding and pharmacokinetics (PK) are important considerations during… |
Toxicology CRS | Reported |
Clinical ORR | 5% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT02858310 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교